We are live on ! Find out more
HTGM

HTG Molecular Diagnostics

Delisted

HTGM was delisted on the 14th of June, 2023.

43 hedge funds and large institutions have $21.5M invested in HTG Molecular Diagnostics in 2019 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 15 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

10% more funds holding

Funds holding: 39 → 43 (+4)

0.06% less ownership

Funds ownership: 45.24% → 45.18% (-0.06%)

1% less capital inflows, than outflows

Capital inflows: $3.33M | Capital outflows: $3.36M

33% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 15

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
43
Holders Change
+4
Holders Change %
+10.26%
% of All Funds
0.93%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
9
Increased
10
Reduced
15
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

HTGM Hedge Fund Activity: Q2 2019 in Review

43 of the 4,627 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics (HTGM) for Q2 2019, worth a combined $21.5M — down 34% from $32.4M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new HTGM positions and 5 closed out — a net gain of 4 holders — while 10 added to existing stakes and 15 trimmed.

The largest buyer was Royce & Associates, opening a new position worth an estimated $1.11M. The largest seller was Fidelity Investments, cutting an estimated $1.41M.

  • 43 institutional investors held HTG Molecular Diagnostics (HTGM) as of Q2 2019, up from 39 in Q1 2019.
  • Funds reported $21.5M of HTG Molecular Diagnostics stock for Q2 2019, down 34% quarter-over-quarter.
  • 9 funds opened new HTG Molecular Diagnostics positions in Q2 2019 and 5 closed out, a net change of +4 holders.
  • The largest HTG Molecular Diagnostics buyer in Q2 2019 was Royce & Associates, an estimated $1.11M added.
  • The largest HTG Molecular Diagnostics seller in Q2 2019 was Fidelity Investments, an estimated $1.41M sold.

Based on aggregated 13F filings for Q2 2019.